SCHEMBL1695083

SCHEMBL1695083

CN(C(=O)O)c1ccc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.46
ALDH1A1 P00352 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
KDM4E B2RXH2 2/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
MAPT P10636 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CES2 O00748 1/20 0.44
CES1 P23141 1/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1137614 0.85 PDK2 (0.47) ALDH1A1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL14385153 0.83 PLAU (0.45) ALDH1A1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL5398870 0.81 CRHBP (0.47) ACHEALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL28393290 0.81 ALDH1A1 (0.41) ACHEALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1177340 0.80 CYP2A6 (0.47) ACHEALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL2097822 0.80 LMNA (0.45) ALDH1A1MEN1KMT2ASMN1; SMN2HTT
SCHEMBL28746540 0.80 MLYCD (0.46) ALDH1A1HTTNPSR1L3MBTL1KDM4E
SCHEMBL12175384 0.80 KDM4E (0.34) ACHEALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL12534118 0.80 MAPT (0.60) ACHEALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL4083016 0.79 KDM4E (0.49) ALDH1A1MEN1KMT2ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4095034-A INSECTICIDES BASF AKTIENGESELLSCHAFT (DT) 1978-06-13 US claimed
JP-57102804-A None JP disclosed
US-12215100-B2 Anticancer compounds PHARMA MAR, S.A. (ES) 2025-02-04 US disclosed
EP-3898613-B1 ANTICANCER COMPOUNDS PHARMA MAR SA (ES) 2023-08-09 EP disclosed
CN-114751920-A Antitumor compounds 法马马有限公司 2022-07-15 CN disclosed
CN-109715605-B Process for preparing carotenoid monoesters 巴斯夫欧洲公司 2022-04-12 CN disclosed
US-20220056021-A1 ANTICANCER COMPOUNDS PHARMA MAR, S.A. (ES) 2022-02-24 US disclosed
EP-3898613-A1 ANTICANCER COMPOUNDS Pharma Mar S.A. (ES) 2021-10-27 EP disclosed
WO-2020127194-A1 ANTICANCER COMPOUNDS PHARMA MAR, S.A. (ES) 2020-06-25 WO disclosed
CN-110621678-A Antitumor compounds 法马马有限公司 2019-12-27 CN disclosed
EP-2231695-B1 ANTITUMORAL COMPOUNDS PHARMA MAR SA (ES) 2013-02-13 EP disclosed
WO-2011147828-A1 SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS PHARMA MAR, S.A. (ES) 2011-12-01 WO disclosed
US-20110207674-A2 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2011-08-25 US disclosed
WO-2010149688-A2 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2010-12-29 WO disclosed
US-20100292163-A1 Antitumoral Compounds PHARMA MAR, S.A. (ES) 2010-11-18 US disclosed
EP-2231695-A1 ANTITUMORAL COMPOUNDS Pharma Mar S.A. (ES) 2010-09-29 EP disclosed
WO-2009077401-A1 ANTITUMORAL COMPOUNDS PHARMA MAR, S.A. (ES) 2009-06-25 WO disclosed
US-7176201-B2 Modulation of anxiety through blockade of anandamide hydrolysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2007-02-13 US disclosed
JP-S57102804-A HERBICIDE COMPOSITION HODOGAYA CHEM CO LTD 1982-06-26 JP disclosed
US-4095034-A INSECTICIDES BASF AKTIENGESELLSCHAFT (DT) 1978-06-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207674-A2 ANTITUMORAL COMPOUNDS TP53, XPO1, TOP2B ACHE 3488/4885ALDH1A1 319/4885MEN1 171/4885
US-20100292163-A1 Antitumoral Compounds TP53, XPO1, TOP2B ACHE 3488/4885ALDH1A1 319/4885MEN1 171/4885
US-20220056021-A1 ANTICANCER COMPOUNDS TP53, MCL1, MYC ACHE 3066/4885ALDH1A1 796/4885MEN1 1162/4885
US-12215100-B2 Anticancer compounds TP53, MCL1, MYC ACHE 3067/4885ALDH1A1 795/4885MEN1 1162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.